{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002624","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-13T12:41:07+00:00","discovered_at":"2026-05-13T12:45:00.365405+00:00","generated_at":"2026-05-13T12:46:17.421261+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site","bullets":["Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.","Tel Aviv Sourasky Medical Center Helsinki Ethics Committee approved planned Phase 2/3 trial of SIL204 in LAPC.","SIL204 is a next-generation siRNA therapy targeting mutated KRAS, most common oncogenic driver in cancers.","Phase 2/3 trial to evaluate SIL204 with standard-of-care chemo using dual-route (intratumoral + systemic) administration.","Israeli Ministry of Health already approved the trial; CTA submitted to Germany; preparing for first patient dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002624","json":"https://secwatch.observer/filing/0001178913-26-002624.json","markdown":"https://secwatch.observer/filing/0001178913-26-002624.md","text":"https://secwatch.observer/filing/0001178913-26-002624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002624/0001178913-26-002624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002624/zk2635307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:46:17.421261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}